Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 3 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2021 Dec 31, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 200.05 214.30 269.00
(-6.6 pct) (+1.4 pct) (-4.6 pct)
Operating 7.13 20.86 11.00
(-65.8 pct) (+22.1 pct) (-44.9 pct)
Recurring 11.49 24.74 15.50
(-53.5 pct) (+22.0 pct) (-40.3 pct)
Net 8.97 14.24 11.50
(-37.0 pct) (-20.0 pct) (-13.6 pct)
EPS 110.43 yen 178.35 yen 141.20 yen
EPS Diluted 110.30 yen 178.12 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10